# US 2019/0338021 A1 · Therapies for treating inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0338021 A1
- Document ID: US20190338021A1
- Status: Published application
- Kind: A1
- Application number: 16/481,439
- Filed: 2018-01-29
- Published: 2019-11-07
- Earliest claimed: 2017-01-27
- Assignees: MicroPharm Limited
- Applicants: Micropharm Limited
- Inventors: John Landon; Ruth Elizabeth Coxon
- Web page: https://patentgrep.com/patent/US20190338021A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/248: {IL-6}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/542: {oral/gastrointestinal}
- C07K 2317/12: isolated from milk
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/23: from birds
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.

## Claims

### Claim 1

An antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit.

### Claim 2 (depends on 1)

The antibody composition according to claim 1, wherein the blood-derived polyclonal antibodies are ovine blood-derived polyclonal antibodies.

### Claim 3 (depends on 1)

The antibody composition according to claim 1, wherein the blood derived polyclonal antibodies are equine blood-derived polyclonal antibodies.

### Claim 4

The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises at least a protease inhibitor.

### Claim 5 (depends on 4)

The antibody composition according to claim 4, wherein the protease inhibitor is one or more selected from the Bowman-Birk inhibitor family of proteins.

### Claim 6

The antibody composition according to any one of the preceding claims formulated as a liquid.

### Claim 7

The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises a means obtainable from egg white.

### Claim 8

The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises egg white, preferably powdered egg white.

### Claim 9

The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises one or more antacid(s).

### Claim 10

The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises one or more of:
a. a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/or chymotrypsin; and/or
b. an antibody that binds to trypsin and/or chymotrypsin and suppresses or inactivates the protease activity of said trypsin and/or chymotrypsin; and/or
c. an antacid.

### Claim 11

The antibody composition according to any one of the preceding claims, wherein the composition comprises an antacid and:
a. a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/or chymotrypsin; and/or
b. an antibody that binds to trypsin and/or chymotrypsin and inactivates the protease activity of said trypsin and/or chymotrypsin.

### Claim 12

The antibody composition according to any one of the preceding claims, wherein the means comprises one or more of ovomucoid, ovostatin, ovomacroglobulin, or combinations thereof.

### Claim 13

The antibody composition according to any one of the preceding claims, wherein at least 5% of the total antibodies present in the composition bind to TNFα.

### Claim 14

The antibody composition according to any one of the preceding claims, wherein at least 10% of the total antibodies present in the composition bind to TNFα.

### Claim 15

A method for manufacturing intact blood-derived polyclonal antibodies that bind to human tumour necrosis factor α (TNFα), said method comprising obtaining a blood sample from a non-human mammal that has been administered an immunogen comprising human TNFα or a fragment thereof.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the non-human mammal is an ovine non-human mammal.

### Claim 17 (depends on 15, 16)

The method according to claim 15 or 16 further comprising obtaining serum from the blood sample.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the non-human mammal is an equine non-human mammal.

### Claim 19 (depends on 15, 18)

The method according to claim 15 or 18 further comprising obtaining plasma from the blood sample.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The method according to any one of claims 15-19 further comprising purifying antibodies using sodium sulphate precipitation or caprylic acid precipitation.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

An antibody obtainable by the method of any one of claims 15-20.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

An antibody composition according to any one of claims 1-14 for use in treating an inflammatory disorder, wherein the antibody composition is orally administered to a subject.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of an antibody composition according to any one of claims 1-14 in the manufacture of a medicament for treating an inflammatory disorder, wherein the antibody composition is orally administered to a subject.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating an inflammatory disorder comprising orally administering an antibody composition according to any one of claims 1-14.

### Claim 25 (depends on 22, 23, 24)

The antibody composition for use, use or method according to any one of claims 22-24, wherein the antibodies and the means for protecting the antibodies are administered simultaneously.

### Claim 26 (depends on 22, 23, 24)

The antibody composition for use, use or method according to any one of claims 22-24, wherein the antibodies and the means for protecting the antibodies are administered separately.

### Claim 27 (depends on 22, 23, 24, 25, 26)

The antibody composition for use, use or method according to any one of claims 22-26, wherein the inflammatory disorder is septic shock.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

The antibody composition for use, use or method according to any one of claims 22-27, wherein the inflammatory disorder is a gastrointestinal disorder, preferably an intestinal disorder.

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The antibody composition for use, use or method according to any one of claims 22-28, wherein the inflammatory disorder is an inflammatory bowel disease, an intestinal infection, a graft vs. host disorder, a disorder caused by: non-steroidal anti-inflammatory drugs, stress, alcohol, bowel surgery, ischaemia and reperfusion, food allergy, or combinations thereof.

### Claim 30 (depends on 22, 23, 24, 25, 26, 27, 28, 29)

The antibody composition for use, use or method according to any one of claims 22-29, wherein the inflammatory disorder is an inflammatory bowel disease selected from ulcerative colitis, Crohn's disease, or combinations thereof.

### Claim 31 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30)

The antibody composition for use, use or method according to any one of claims 22-30, wherein the antibody composition is administered to a subject at a dose of 2 g or less daily.

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The antibody composition for use, use or method according to any one of claims 22-31, wherein the antibody composition is administered to a subject at a dose of 1 g or less daily.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A kit comprising an antibody composition according to any one of claims 1-14, and instructions for use of same.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A foodstuff comprising an antibody composition according to any one of claims 1-14.

### Claim 35 (depends on 34)

The foodstuff according to claim 34, wherein the foodstuff is a dairy product, preferably a dairy product selected from yogurt, cheese, or milk.

### Claim 36 (depends on 34, 35)

The foodstuff according to claim 34 or 35 further comprising a probiotic, and optionally a prebiotic.
